Resources
69 Results (showing 11 - 20)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 12/24/2020 (updated 4/4/2024)
The Townhall TeleECHO presentation will introduce a monthly interactive opportunity for clinicians and their support staff to address challenges and share solutions and successes to gain confidence in addressing OUD with MOUD. The Behavioral Health Data Learning Collaborative presentation will introduce goals of understanding data and data sharing, use of indicators and data sources, and data driven programming and quality improvement. Open discussion will follow each presentation.
Posted 11/11/2021 (updated 4/3/2024)
This session presented resources and elements to consider when planning to collaborate with a local jail to establish pre- and post-release programing and coordination of care and services for individuals with SUD. A real-world example was presented by an RCORP grantee showcasing its First Day Forward Program.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Rural Community Opioid Response Program (RCORP) grantees discussed their efforts and initiatives working with criminal justice and corrections agencies to engage individuals who are incarcerated.
Posted 11/11/2020 (updated 4/3/2024)
West Virginia leads the nation in overdose death rate and both counties where participants were interviewed for this study were considered to be at risk for an HIV outbreak among people who inject drugs. This study asked the question ‘What on-the-ground environmental factors among PWIH could be contributing to this overdose rate?
Posted 11/11/2020 (updated 4/3/2024)
This report describes decedent demographic characteristics and circumstances surrounding overdose deaths during January–June 2019 among 25 jurisdictions participating in CDC’s State Unintentional Drug Overdose Reporting System (SUDORS),† and it highlights the involvement of opioids and stimulants, separately and in combination.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/19/2021 (updated 4/2/2024)
Drug overdose deaths in the United States hit a record high in 2017, with an estimated 72,000 deaths. Over two-thirds of those deaths, roughly 47,600, were due to opioids.These staggering numbers continued in 2018, as over 67,000 drug overdose deaths occurred, and opioids were involved in rough 46,800 of those overdose deaths.
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications.
Posted 6/17/2021 (updated 4/2/2024)
Fueled by misinformation, fentanyl panic has harmed public health through complicating overdose rescue while rationalizing hyper-punitive criminal laws, wasteful expenditures, and proposals to curtail vital access to pain pharmacotherapy. To assess misinformation about health risk from casual contact with fentanyl, we characterize its diffusion and excess visibility in mainstream and social media.